The Impact of TP53 Mutations and Use of the TP53Mutation-Reactivating Agent APR-246 on Metastatic Castrate-Sensitive Prostate Cancer

被引：0
|
作者：
Hoang, T. [1 ]
Sutera, P. [2 ]
Nguyen, T. [1 ]
Chang, J. H. [3 ]
Jagtap, S. [3 ]
Song, Y. [3 ]
Shetty, A. [3 ]
Chowdhury, D. D. [3 ]
Chan, A. [3 ]
Carrieri, F. A. A. [4 ]
Song, D. [5 ]
DeWeese, T. L. [5 ]
Lafargue, A. [5 ]
Van der Eecken, K. [6 ]
Bunz, F. [7 ]
Ost, P. [8 ]
Tran, P. T. [5 ,9 ]
Deek, M. P. [10 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Univ Maryland, Baltimore, MD 21201 USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA
[6] Univ Ghent, Ghent, Belgium
[7] Johns Hopkins Med, Baltimore, MD USA
[8] Ghent Univ Hosp, Dept Radiat Oncol, Ghent, Belgium
[9] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA
[10] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2966
引用
收藏
页码：E443 / E443
页数：1
相关论文
共 50 条
  • [31] Functional genomics of TP53 mutations and its impact in breast cancer progression
    Pal, Anasuya
    Gonzalez-Malerva, Laura
    Eaton, Seron
    Guzman, Mayra
    Chow, Donald
    Yin, Hongwei
    Park, Jin
    Anderson, Karen
    LaBaer, Joshua
    CANCER RESEARCH, 2015, 75
  • [32] Prognostic Impact of TP53 Mutations and Tumor Mutational Load in Colorectal Cancer
    Ho, Vincent
    Chung, Liping
    Lim, Stephanie H.
    Ma, Yafeng
    Wang, Bin
    Lea, Vivienne
    Abubakar, Askar
    Ng, Weng
    Lee, Mark
    Roberts, Tara L.
    Chua, Wei
    Lee, C. Soon
    GASTROINTESTINAL DISORDERS, 2022, 4 (03): : 165 - 179
  • [33] Prognostic value of tumour suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
    Gonzalez Velez, M. G.
    Kosiorek, H. E.
    Egan, J.
    Bryce, A. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Are mutations of the TP53 tumour suppressor gene risk factors for prostate cancer formation?
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 183 - 183
  • [35] Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
    Åsa Fransson
    Daria Glaessgen
    Jessica Alfredsson
    Klas G. Wiman
    Svetlana Bajalica-Lagercrantz
    Nina Mohell
    Journal of Ovarian Research, 9
  • [36] APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation
    Teruyuki Kobayashi
    Tomoki Makino
    Kotaro Yamashita
    Takuro Saito
    Koji Tanaka
    Tsuyoshi Takahashi
    Yukinori Kurokawa
    Makoto Yamasaki
    Kiyokazu Nakajima
    Eiichi Morii
    Hidetoshi Eguchi
    Yuichiro Doki
    British Journal of Cancer, 2021, 125 : 1523 - 1532
  • [37] APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation
    Kobayashi, Teruyuki
    Makino, Tomoki
    Yamashita, Kotaro
    Saito, Takuro
    Tanaka, Koji
    Takahashi, Tsuyoshi
    Kurokawa, Yukinori
    Yamasaki, Makoto
    Nakajima, Kiyokazu
    Morii, Eiichi
    Eguchi, Hidetoshi
    Doki, Yuichiro
    BRITISH JOURNAL OF CANCER, 2021, 125 (11) : 1523 - 1532
  • [38] Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.
    Hammer, Liat
    Rebernick, Ryan
    McFarlane, Matthew
    Westbrook, Thomas
    Hazime, Munna
    Hammoud, Tanya
    Chiu, Pin-en
    Xavier, Owens
    Wu, Yi-Mi
    Robinson, Dan R.
    Spratt, Daniel Eidelberg
    Alva, Ajjai Shivaram
    Jackson, William C.
    Reichert, Zachery R.
    Alumkal, Joshi J.
    Chinnaiyan, Arul
    Cieslik, Marcin
    Dess, Robert Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [39] Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
    Fransson, Asa
    Glaessgen, Daria
    Alfredsson, Jessica
    Wiman, Klas G.
    Bajalica-Lagercrantz, Svetlana
    Mohell, Nina
    JOURNAL OF OVARIAN RESEARCH, 2016, 9
  • [40] Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
    Sallman, David A.
    DeZern, Amy E.
    Garcia-Manero, Guillermo
    Steensma, David P.
    Roboz, Gail J.
    Sekeres, Mikkael A.
    Cluzeau, Thomas
    Sweet, Kendra L.
    McLemore, Amy F.
    McGraw, Kathy
    Puskas, John
    Zhang, Ling
    Yao, Jiqiang
    Mo, Qianxing
    Nardelli, Lisa
    Al Ali, Najla
    Padron, Eric
    Korbel, Greg
    Attar, Eyal C.
    Kantarjian, Hagop M.
    Lancet, Jeffrey E.
    Fenaux, Pierre
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2019, 134
12345